Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. - Wikidata - wikimedia - TriplyDB

Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.

Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.

http://www.wikidata.org/entity/Q39904254

about

Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer Can urinary PCA3 supplement PSA in the early detection of prostate cancer?Prediction models in cancer care.Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.Prostate cancer risk prediction in a urology clinic in Mexico.The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting A simple decision analytic solution to the comparison of two binary diagnostic tests.Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.Updating risk prediction tools: a case study in prostate cancer.External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.Risk-based prostate cancer screening.Risk-based prostate cancer screening: who and how?Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy.A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.

P2860

Q27304922-E3F5155F-17A8-433D-BE73-BA274B81A0E2 Q34692263-1661E138-C75D-4A6F-BFDB-5DBB3EDBD809 Q35292878-D6CB1EEB-8583-452B-BC23-7CF923262963 Q35921826-3B8C132F-1AAC-458E-B8D9-7D795511BBC9 Q35940811-B63042F8-F744-450B-8F44-8B9AEB0FCEBD Q35996067-1DAA36AA-34CD-4AE0-854E-AE3944F55D86 Q36185925-2BD6F487-5636-43E9-9D80-622AB4FEF294 Q36492300-A07380E2-02A1-4BBD-A9FA-3413937FBFD6 Q36739758-DA24876A-83B9-4147-A9FB-7B83615E846B Q37001612-A3C77248-ED56-492C-8BB9-63F51CFEB7FA Q37025404-7E36CABC-DDA2-4B2A-80F7-64BFBD03380B Q37074118-3026841C-6172-4DE4-8BA2-2FB93A2395C1 Q37075718-A72BFBD9-B890-4115-BF52-148989D6E36C Q37252155-99C5FC5F-506F-4C1D-B276-ADB83C831895 Q37279076-79A9FBDA-B4E5-4D29-A861-78EBF6E7CDC1 Q37414994-6514F55D-F8AB-4A46-9251-CB43567C0869 Q37963657-A3D646F4-CB93-4511-A7F9-C65E05D45A1F Q38093463-36FF33E3-9DD0-443C-BDD5-A18F0FEC62B0 Q38268839-59C9F8B1-D0EE-43BE-9E95-BA975C8B50BF Q38950693-4C02D929-CA80-4CAF-A2A2-8DE4E65CF277 Q39377009-57A70397-161F-4388-9F2F-D5F1052334E7 Q39963357-5795A24D-7698-4C91-8408-9EBC6F7BDFC9 Q40037072-7F000619-EF8A-4318-9A91-66B4A0400B6D Q40087634-A3078432-83C7-4970-A47E-9C111159C26F Q40199490-08FC7C5E-21A0-4718-86DA-069026BC982A

P2860

Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.

http://www.wikidata.org/entity/Q39904254

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Validation in a multiple urolo ...... ing prostate cancer detection.

@en

Validation in a multiple urolo ...... ing prostate cancer detection.

@nl

type

label

Validation in a multiple urolo ...... ing prostate cancer detection.

@en

Validation in a multiple urolo ...... ing prostate cancer detection.

@nl

prefLabel

Validation in a multiple urolo ...... ing prostate cancer detection.

@en

Validation in a multiple urolo ...... ing prostate cancer detection.

@nl

P1433

Q39904254-068E0DEB-CEE9-4FD9-802E-92CCC51B731A

P1476

Q39904254-6DB0CEF7-0503-470D-BD9C-C0A1E201A031

P2093

Q39904254-0F842D9C-5455-4FDD-BAFC-7CFD5C341321

Q39904254-23D902BF-7565-4DD0-86F8-79D5E978C0F5

Q39904254-4C720C88-FAA8-4FE9-B6CE-E9D31DA8A091

Q39904254-51CE9E63-205E-4809-83F6-4AC452B27E88

Q39904254-62D447D9-5AE6-4224-821E-8464B3EF8D3A

Q39904254-966F3A2B-A084-44E0-B180-7DD258F8ADF2

Q39904254-9F97FAFB-53F1-4885-9EF3-7B11863D5A4E

Q39904254-B3DDB473-09E7-41F8-8A1D-5D48B786E9CF

Q39904254-F630F31F-A10F-4B4E-8BD3-FA2857EB6E34

P2860

Q39904254-01E58892-362B-4299-80E6-53EE941A289A

Q39904254-0AEDF9B2-2985-4F12-8B4A-7FBECDBBFDFD

Q39904254-3985525F-D7C5-4D2D-9734-EC1BDB267B66

Q39904254-49305B5C-FC07-46AF-ADF1-13F5E7958D65

Q39904254-5142B6D2-F33A-4E24-81EB-D430B64C7155

Q39904254-74C9E262-76EA-4296-86B4-E8CE8C5AC60A

Q39904254-790119FF-2E95-4475-8264-DBDF8E5389AB

Q39904254-7C097674-66B4-46BF-9415-11809478E6A4

Q39904254-8EDFDC89-AF85-49F3-BF32-8677CBCED561

Q39904254-9110DA92-9CE1-4FB5-B319-A6346B221C57

P304

Q39904254-B62C5EC0-1987-41F2-BF9A-A83907E09B36

P31

Q39904254-87A6FF69-B3F6-400C-A09A-4C46377E2084

P356

Q39904254-B1DD6C08-D7F8-4241-96EF-09D7762BC1D5

P407

Q39904254-584924F1-FB3B-4B0D-8E58-C872395AB61C

P433

Q39904254-05BF9704-4BE7-4A9C-A9A6-85D3FDFE9E06

P478

Q39904254-3D3E95C9-5E71-4766-9742-09B464650358

P50

Q39904254-41C729F2-FF65-4905-8046-AA7805DD74A0

Q39904254-D5E53023-EAEC-4D02-AE28-AE4B33BC124F

P577

Q39904254-B1E5B196-175F-4AA8-942D-A683F9418963

P698

Q39904254-3F9D370B-62F7-44BF-A568-032BF708C461

P932

Q39904254-A81E811B-683E-41BA-993C-2A1D625D5356

P356

J.JURO.2009.08.056

P1433

The Journal of Urology

P1476

Validation in a multiple urolo ...... ing prostate cancer detection.

@en

P2093

Gerrardina Bueti

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Tang

http://www.w3.org/2001/XMLSchema#string

John T Wei

http://www.w3.org/2001/XMLSchema#string

Martin G Sanda

http://www.w3.org/2001/XMLSchema#string

Meredith M Regan

http://www.w3.org/2001/XMLSchema#string

Michael Kearney

http://www.w3.org/2001/XMLSchema#string

Prakash V Nair

http://www.w3.org/2001/XMLSchema#string

Stephen J Eyre

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Screening and prostate-cancer mortality in a randomized European study

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

The influence of finasteride on the development of prostate cancer.

Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.

P304

2653-2658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2009.08.056

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19836788

http://www.w3.org/2001/XMLSchema#string

P932

5890334

http://www.w3.org/2001/XMLSchema#string